Characterization of the Rhesus Monkey CYP3A64 Enzyme: Species Comparisons of CYP3A Substrate Specificity and Kinetics Using Baculovirus-Expressed Recombinant Enzymes
Authors:
- Brian CarrBCBrian Carr
- Ryan NorcrossRNRyan Norcross
- Yulin FangYFYulin Fang
- Ping LuPLPing Lu
- A. David RodriguesARA. David Rodrigues
- Magang ShouMSMagang Shou
- Tom RushmoreTRTom Rushmore
- Catherine Booth-GentheCBCatherine Booth-Genthe
Open Access
- 1 October 2006
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 34 (10) , 1703-1712
Abstract
The rhesus monkey (Macaca mulatta) is a primate species used extensively as a preclinical safety species in drug development. In this report, we describe the cloning, expression, and characterization of CYP3A64 (AY334551), a CYP3A4 homolog expressed in rhesus liver. The deduced amino acid sequence was found to be 93% similar to human CYP3A4, 83% similar to human CYP3A5, and identical to the previously reported cynomolgus monkey CYP3A8 (Komori et al., 1992). The substrate specificity of CYP3A64 for testosterone (0–250 μM), midazolam (0–200 μM), nifedipine (0–200 μM), and 7-benzoxy-4-trifluoromethylcoumarin (0–200 μM) were compared with recombinant enzymes from rat (CYP3A1, CYP3A2), dog (CYP3A12, CYP3A26), rabbit (CYP3A6), and human (CYP3A4, CYP3A5). Immunoinhibition and chemical inhibition of CYP3A64 was demonstrated using the inhibitory monoclonal antibody (MAb) 10-1-1 (anti-3A4) and ketoconazole (0–10 μM). The utility of CYP3A64 to be used as a standard in monkey induction assays was shown and the concentration of CYP3A64 protein in rhesus liver microsomes was estimated to be 72 pmol/mg protein. In summary, these results support the utilization of rhesus monkey CYP3A64 for in vitro drug metabolism studies and provide a more complete understanding of CYP3A substrate specificities and species differences in metabolic capabilities.Keywords
This publication has 43 references indexed in Scilit:
- Human Cytochrome P450 Enzymes2007
- CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese populationClinica Chimica Acta, 2005
- Midazolam Oxidation by Cytochrome P450 3A4 and Active-Site Mutants: an Evaluation of Multiple Binding Sites and of the Metabolic Pathway That Leads to Enzyme InactivationMolecular Pharmacology, 2002
- Phenylalanine and Tryptophan Scanning Mutagenesis of CYP3A4 Substrate Recognition Site Residues and Effect on Substrate Oxidation and CooperativityBiochemistry, 2001
- The use of heterologously expressed drug metabolizing enzymes— state of the art and prospects for the futurePharmacology & Therapeutics, 1999
- CYP3A4 drug interactions: correlation of 10 in vitro probe substratesBritish Journal of Clinical Pharmacology, 1999
- Cytochromes P450 Expression SystemsAnnual Review of Pharmacology and Toxicology, 1995
- Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liverBiochemical Pharmacology, 1994
- Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamilyBiochemical Pharmacology, 1994
- Molecular cloning of monkey liver cytochrome P-450 cDNAsBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1992